drugset / Trial / NCT00774007
A Randomized Controlled Pilot Trial of Mesalazine in Patients With Irritable Bowel Syndrome
Phase 2/3
Completed
20 enrolled
SOFAR S.p.A.
IRCCS Azienda Ospedaliero-Universitaria di Bologna · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Emerging evidence indicates the presence of low-grade mucosal inflammation and its pathogenetic role in IBS. The aim of this pilot study is to provide that mesalazine treatment of IBS patients reduces low grade colonic inflammation.
Timeline
- Start
- 2004-09
- Primary completion
- 2005-11
- Completion
- 2005-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Mesalamine | Small molecule | 800 mg | — |